Head and Neck Cancer is cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx [voice box]).
When the human papillomavirus (HPV) is found in cancer tumours of the tonsil and base of the tongue, patients are more likely to survive following treatment.
Varian Medical Systems has received FDA 510(k) clearance for the Acuros® XB advanced dose calculation algorithm which can complete a RapidArc® treatment plan two to three times faster than conventional planning algorithms. Varian has incorporated the Acuros algorithm for external beam radiotherapy treatment planning into its market-leading Eclipse™ treatment planning system on exhibit at the 52nd annual meeting of the American Society for Radiation Oncology (ASTRO) in San Diego October 31 - November 4.
Developing a molecular fingerprint for head and neck cancer tumors could help improve diagnosis and treatment for this deadly and often-times disfiguring form of cancer, according to researchers at Henry Ford Hospital in Detroit.
A popular cancer drug could be produced cheaply and sustainably using stem cells derived from trees, a study suggests. Researchers have isolated and grown stem cells from a yew tree whose bark is a natural source of the anticancer compound paclitaxel. The development could enable the compound to be produced on a commercial scale at low cost, with no harmful by-products.
Amar Rewari, MD, MBA, a researcher from The Cancer Institute of New Jersey (CINJ), has been chosen to receive the Clinical Award in Clinical/Basic Science Research at the 52nd Annual Meeting of The American Society for Radiation Oncology (ASTRO) in San Diego next month. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.
BSD Medical Corporation announced today that the University Medical Center (UMC) of Göttingen, Germany, has purchased a BSD-500 Hyperthermia System (BSD-500). UMC was established in 1732 and is a center of scientific excellence in Europe and the most prominent medical center in Lower Saxony, Germany.
CEL-SCI Corporation announced today it has received approval from seven hospital Institutional Review Boards in India to begin enrollment of subjects for a Phase III clinical trial of Multikine, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer.
Curcumin, the major component in the spice turmeric, when combined with the drug Cisplatin enhances the chemotherapy's suppression of head and neck cancer cell growth, researchers with UCLA's Jonsson Cancer Center have found.
The American Society for Radiation Oncology (ASTRO) has named Brian Hill of Newport Beach, Calif., as its 2010 Survivor Circle Award winner. Hill will be recognized with a trophy and a $1,000 prize during the Awards Ceremony on Tuesday, November 2, 2010, during ASTRO's 52nd Annual Meeting in San Diego. He has chosen to donate the funds from the award to benefit The Oral Cancer Foundation, the nonprofit he started a decade ago.
Genmab A/S announced today an update on the potential regulatory pathway for zalutumumab following preliminary, non-binding discussions with a number of selected national European regulatory authorities and the FDA.
Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has received initial prescriptions for its lead product, MuGard – an FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of radiotherapy and/or chemotherapy.
CEL-SCI Corporation announced today it has received approval from the first Taiwanese Institutional Review Board ("IRB") to begin enrollment of subjects for a Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. An IRB is a group formally designated by an institution to review and monitor research involving human subjects and to ensure protection of their rights and welfare.
Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care, announced the highlights from a poster presentation on European clinical experience of MuGard at this year's European Society of Medical Oncology Conference in Milan, Italy.
Boehringer Ingelheim Pharmaceuticals, Inc. announced today results from two clinical trials for its investigational cancer compound afatinib* (BIBW 2992) presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy.
Eli Lilly and Company announced today that its global Phase III trial evaluating ALIMTA (pemetrexed for injection) in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (SCCHN) did not meet its primary endpoint for overall survival. Data were presented for the first time today at the 35th Annual Meeting of the European Society for Medical Oncology (ESMO).
Amgen today announced that results from several important studies from the Company's ncology portfolio will be presented at the 35th European Society for Medical Oncology (ESMO) Congress, Oct. 8-12, 2010, in Milan, Italy.
Merck Serono, a division of Merck KGaA, Darmstadt, Germany announces today that it will be presenting new data from several studies of Erbitux (cetuximab) in a range of solid tumor types including the first Phase II data in breast and prostate cancers. These data will be presented at the forthcoming 35th European Society for Medical Oncology Congress (ESMO) in Milan, October 8-12, 2010.
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that researchers have identified two unique gene clusters that differentiated subjects who responded to treatment in the Company’s phase 2a proof of concept study of SCV-07 for the prevention of severe oral mucositis (OM; WHO grades 3-4) in patients with advanced head and neck cancer.
IsoRay Inc. a medical isotope company and the exclusive manufacturer of Cesium-131 used in internal radiation therapy for the treatment of lung, colon, head and neck, and prostate cancers, ocular melanoma, and other malignant disease through the use of its proprietary radioisotope technology, announced its financial results for the year ended June 30, 2010.
Head and neck cancer outcomes associated with race may be more closely linked to social and behavioral factors than biological differences, especially for African Americans, according to a new Henry Ford Hospital study.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.